The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

TCTMD's Yael Maxwell, Laura McKeown, Michael O'Riordan, Caitlin Cox, and Todd Neale describe their standout stories.

With new data from several studies this year, researchers are chipping away at the question of when to revascularize and how.

Mamas Mamas, Martha Gulati, and Benoy Shah review the most impactful CV research of the year.

One in 20 of the young adult participants had arrhythmias—some occurred many hours later when they were sobering up.

Mean CV health score, which ranges from 0 (worst) to 100 (best), was 82.6 in early childhood, 84.1 in mid-childhood, 82.0 in ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Complication rates, including bleeding, were significantly lower when the radial artery was used over a second femoral ...

As an end-of-year gift, one fellow offers bits of advice he’s gotten that have helped him succeed in interventional ...